Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer

Current Opinion in Oncology
Rafael RosellMiquel Taron

Abstract

Classic activating mutations in the form of deletions in exon 19 or a missense mutation L858R in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) predict dramatic responses to EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib. We review here the clinical benefits of targeted therapy with erlotinib and gefitinib in white and Asian nonsmall-cell lung cancer patients. Two separate analyses of pooled data from small phase II prospective studies show that therapy with gefitinib and erlotinib induces responses in over 70% of nonsmall-cell lung cancer patients harboring classic EGFR mutations, with progression-free survival ranging from 9 to 13 months and median survival of around 23 months. Two separate studies in white and Asian patients have recently confirmed that these subgroups of patients attain response rates of 70% with erlotinib and gefitinib, including complete responses, progression-free survival of up to 14 months, and median survival of up to 27 months. The serial monitoring of EGFR mutations in the blood will permit the assessment of molecular responses and be an important tool for the surveillance of clinical progression. Nonsmall-cell lung cancer with EGFR mutations constitute a ...Continue Reading

References

Jul 31, 2004·Science·Raffaella SordellaJeffrey Settleman
Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miguel TaronTeresa Moran
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gregory J RielyVincent A Miller
Dec 7, 2007·The Journal of Clinical Investigation·Sizhi Paul GaoJacqueline F Bromberg
Jan 31, 2008·JAMA : the Journal of the American Medical Association·Aaron J SchetterCurtis C Harris
May 7, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistThomas J Lynch
Jul 4, 2008·The New England Journal of Medicine·Shyamala MaheswaranDaniel A Haber
Nov 4, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Miguel A Molina-VilaRafael Rosell
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tan Min ChinJeffrey Settleman
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel B CostaSusumu Kobayashi
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Akira InoueUNKNOWN North East Japan Gefitinib Study Group
Apr 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yanan KuangPasi A Jänne
May 2, 2009·Science·David M Livingston
May 6, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hua BaiJie Wang
May 12, 2009·Expert Opinion on Biological Therapy·Maria Angelica Cortez, George Adrian Calin
Jun 2, 2009·Nature Reviews. Clinical Oncology·Helena LinardouSamuel Murray
Jun 18, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Satoshi MoritaToshihiro Nukiwa
Jun 25, 2009·Cancer Research·Xianglin WuFergus J Couch
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Jun 26, 2009·Nature·Kenneth L ScottLynda Chin
Jul 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Katharina SchmidMartin Filipits
Jul 15, 2009·Proceedings of the National Academy of Sciences of the United States of America·Masahiro SeikeCurtis C Harris
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David M JackmanBruce E Johnson
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Aug 21, 2009·The New England Journal of Medicine·Adi F Gazdar
Aug 21, 2009·The New England Journal of Medicine·Rafael RosellUNKNOWN Spanish Lung Cancer Group

❮ Previous
Next ❯

Citations

Jun 1, 2011·Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu·Zhi-Jie WangJie Wang
Feb 17, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Rafael RosellMiquel Tarón
Oct 23, 2010·Nature Reviews. Cancer·William Pao, Juliann Chmielecki
Sep 11, 2013·Proceedings of the National Academy of Sciences of the United States of America·Monica Red BrewerWilliam Pao
Mar 25, 2014·Expert Opinion on Investigational Drugs·Frances E Lennon, Ravi Salgia
Jan 18, 2011·Expert Opinion on Investigational Drugs·Rina Barouch-Bentov, Karsten Sauer
Nov 17, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Angela ZupaEmanuel Petricoin
Mar 13, 2012·Expert Opinion on Pharmacotherapy·Monika JoshiChandra P Belani
May 19, 2012·Pharmacogenomics·Clara MayoRafael Rosell
Oct 27, 2010·Annals of the New York Academy of Sciences·Rafael RosellMiquel Taron
Mar 3, 2011·Nature Reviews. Clinical Oncology·Thomas TurszJean-Charles Soria
Jul 1, 2010·Expert Opinion on Pharmacotherapy·Athanasios Kotsakis, Vassilis Georgoulias
Mar 22, 2014·Molecular and Clinical Oncology·Paola UliviDino Amadori
Apr 15, 2010·Cancer Research·Kasisomayajula ViswanathUNKNOWN Writing Committee for the AACR Task Force on Tobacco and Cancer
Sep 6, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Valentina PirazzoliKaterina Politi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Rafael RosellSpanish Lung Cancer Group
The New England Journal of Medicine
Tony S MokMasahiro Fukuoka
The New England Journal of Medicine
Frances A ShepherdNational Cancer Institute of Canada Clinical Trials Group
© 2022 Meta ULC. All rights reserved